Monday, May 7, 2012

Sanofi Japan initates clinical trials to evaluate the use of hydroxychloroquine sulfate in Japanes patients.

Sanofi Japan has initiated clinical trials to evaluate the use of hydroxychloroquine sulfate in Japan. hydroxychloroquine sulfate is an age old drug, but not approved in Japan. The drug is already used outside Japan as a DMARD for Rheumatoid Arthritis, treatment for Malaria and  lupus erythematosus suppressant. This drug is not approved in Japan as it was not evaluated in Clinical trials, but it is currently being imported for use